RAS testing in metastatic colorectal cancer: Excellent reproducibility amongst 17 Dutch pathology centers

Oncotarget

Volumn 6, Issue 17, 2015, Pages 15681-15689

  Boleij, Annemarie ^a   Tops, Bastiaan B J ^a   Rombout, Paul D M ^a   Dequeker, Elizabeth M ^b   Ligtenberg, Marjolijn J L ^a   van Krieken, J Han ^a   van Noesel, C J M ^c   Scheidel Jacobse, C C ^d   Kummer, J A ^d   Roepman, P ^d   Prinsen, C F M ^e   van den Berg van Erp, S H M ^e   van Gorp, J M H H ^f   Nederlof, P M ^g   Caspers, E ^h   Dinjens, W N M ⁱ   Beerens, E C W ⁱ   't Hart, N A ^j   van den Brule, A J C ^k   van der Geize, R ^l   Riemersma, S A ^l   van Wezel, T ^m   Morreau, H ^m   van Eijk, R ^m   Jeuken, J W M ⁿ   Dirkx, A ^o   Klomp, M ^p   van Blokland, W T M ^q   ter Elst, A ^r   Schuuring, E ^r   Diepstra, A ^r   Heideman, D A M ^s   van Grieken, N C T ^s   Sie, D ^s   more..

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f DEPARTMENT OF SURGERY   (Netherlands)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

^h Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j Isala Hospitals   (Netherlands)

^k JEROEN BOSCH HOSPITAL   (Netherlands)

^l Laboratory for Pathology Oost Nederland   (Netherlands)

^m LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ Stichting Laboratoria voor Pathologie en Medische Microbiologie   (Netherlands)

^o Laboratory for Pathology   (Netherlands)

^p RIJNSTATE HOSPITAL   (Netherlands)

^q UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^r UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^s VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Colorectal cancer; Metastasis; Next generation sequencing; Quality control; RAS

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; CETUXIMAB; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NRAS PROTEIN, HUMAN; PANITUMUMAB; PROTEIN P21;

ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DNA SEQUENCE; GENETIC SCREENING; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; MUTATION; NETHERLANDS; NUCLEOTIDE SEQUENCE; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CETUXIMAB; COLORECTAL NEOPLASMS; GENETIC TESTING; GTP PHOSPHOHYDROLASES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MEMBRANE PROTEINS; MUTATION; NETHERLANDS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA;

EID: 84934342521     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3804     Document Type: Article

References (25)

1. Stintzing S, Kapaun C, Laubender RP, Jung A, Neumann J, Modest DP, Giessen C, Moosmann N, Wollenberg A, Kirchner T, Heinemann V. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu. Int. J. Cancer 2013; 132: 236-245.
2. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon J-L, Hecht JR, Yu H, Oliner KS, Go WY. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal. J. Clin. Oncol. 2014; 32: 2240-2247.
3. Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Blasinska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 2013; 369: 1023-1034.
4. European Medicines Agency. Vectibix-Panitumumab. 2013.Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000741/human_med_001128.jsp&mid=WC0b01ac058001d124.
5. European Medicines Agency. Erbitux-Cetuximab. 2013.Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000558/human_med_000769.jsp&mid=WC0b01ac058001d124.
6. Querings S, Altmüller J, Ansén S, Zander T, Seidel D, Gabler F, Peifer M, Markert E, Stemshorn K, Timmermann B, Saal B, Klose S, Ernestus K, Scheffler M, Engel-Riedel W, Stoelben E, Brambilla E, Wolf J, Nürnberg P, Thomas RK. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One 2011; 6: e19601.
7. Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, Murphy KM. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J. Mol. Diagn. 2010; 12: 425-432.
8. Dijkstra JR, Heideman DAM, Meijer GA, Boers JE, 't Hart NA, Diebold J, Hirschmann A, Hoefler G, Winter G, Miltenberger-Miltenyi G, Pereira S V, Richman SD, Quirke P, Rouleau EL, Guinebretiere JM, Tejpar S, Biesmans B, van Krieken JHJM. KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. Virchows Arch. 2013; 462: 39-46.
9. Van Krieken JH, Siebers AG, Normanno N. European consensus conference for external quality assessment in molecular pathology. Ann. Oncol. 2013; 24: 1958-1963.
10. Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T, Pisconti S, Giuliani F, Barone C, Cartenì G, Rachiglioa M, Montesarchio V, Tonini G, Rizzi D, Cinieri S, Bordonaro R, Febbraro A, De Vita F, Orditura M, Fenizia F, Lambiase M, Rinaldi A, Tatangelo F, Botti G, Colucci G. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. Ann. Oncol. 2014; 25: 1756-1761.
11. Tembuyser L, Ligtenberg MJL, Normanno N, Delen S, van Krieken JH, Dequeker EMC. Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer. J. Mol. Diagn. 2014; 16: 371-377.
12. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008; 26: 1626-1634.
13. Ciardiello F, Tejpar S, Normanno N, Mercadante D, Teague T, Wohlschlegel B, Van Cutsem E. Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Target. Oncol. 2011; 6: 133-145.
14. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11: 753-762.
15. Peeters M, Douillard J-Y, Van Cutsem E, Siena S, Zhang K, Williams R, Wiezorek J. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J. Clin. Oncol. 2013; 31: 759-765.
16. Wong A, Ma BBY. Personalizing therapy for colorectal cancer. Clin. Gastroenterol. Hepatol. 2014; 12: 139-144.
17. Negru S, Papadopoulou E, Apessos A, Stanculeanu DL, Ciuleanu E, Volovat C, Croitoru A, Kakolyris S, Aravantinos G, Ziras N, Athanasiadis E, Touroutoglou N, Pavlidis N, Kalofonos HP, Nasioulas G. KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. BMJ Open 2014; 4: e004652.
18. Vaughn CP, Zobell SD, Furtado L V, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes. Chromosomes Cancer 2011; 50: 307-312.
19. Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J, Humblet Y, Van Laethem J-L, André T, Wiezorek J, Reese D, Patterson SD. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin. Cancer Res. 2013; 19: 1902-1912.
20. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
21. Thunnissen E, Bovée JVMG, Bruinsma H, van den Brule AJC, Dinjens W, Heideman DAM, Meulemans E, Nederlof P, van Noesel C, Prinsen CFM, Scheidel K, van de Ven PM, de Weger R, Schuuring E, Ligtenberg M. EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy. J. Clin. Pathol. 2011; 64: 884-892.
22. Viray H, Li K, Long TA, Vasalos P, Bridge JA, Jennings LJ, Halling KC, Hameed M, Rimm DL. A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells. Arch. Pathol. Lab. Med. 2013; 137: 1545-1549.
23. Smits AJJ, Kummer JA, de Bruin PC, Bol M, van den Tweel JG, Seldenrijk KA, Willems SM, Offerhaus GJA, de Weger RA, van Diest PJ, Vink A. The estimation of tumor cell percentage for molecular testing by pathologists is not accurate. Mod. Pathol. 2014; 27: 168-174.
24. Viera AJ, Garrett JM. Understanding Interobserver Agreement: The Kappa Statistic. 2005; 37: 360-363.
25. Sie D, Snijders PJF, Meijer GA, Doeleman MW, van Moorsel MIH, van Essen HF, Eijk PP, Grünberg K, van Grieken NCT, Thunnissen E, Verheul HM, Smit EF, Ylstra B, Heideman DAM. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cell. Oncol. (Dordr). 2014; 37: 353-361.